Edoxaban and Capmatinib: Interaction Details
- Edoxaban
- Savaysa
- Capmatinib
- Tabrecta
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Edoxaban and Capmatinib interaction:
What Happens When You Take Edoxaban With Capmatinib
What can happen when they are taken together (rated Major)
Increased exposure and an increased risk of increased adverse reactions
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Giving capmatinib together with a P-gp substrate raised exposure to that substrate, a change that could heighten the substrate's adverse reactions.1 With digoxin (a P-gp substrate), digoxin rose by 74% and its (0 to inf) rose by 47%.12 Where combined use of capmatinib and a P-gp substrate cannot be avoided and even small shifts in concentration of that substrate could result in serious adverse reactions, the dose of the P-gp substrate should be reduced according to its recommendations.1
The Edoxaban and Capmatinib Interaction, Explained
Edoxaban (Savaysa) is a that helps prevent clots and strokes. Capmatinib (Tabrecta) is a cancer medicine. Capmatinib can slow down a "pump" in your body (called ) that helps clear edoxaban. If that pump slows, more edoxaban may stay in your blood. That could raise your risk of bleeding, like easy bruising, nosebleeds, bleeding gums, or dark stools.
This concern is mostly based on how these drugs work, not on studies of these two drugs together. The good news: your care team can manage this. Your edoxaban dose may need to be adjusted and individualized, and your team may monitor you more closely. Keep taking your medicines as prescribed and talk with your pharmacist or doctor.
Mechanism: Capmatinib inhibits -mediated efflux. Edoxaban is a P-gp , so is expected to increase edoxaban exposure (/) and bleeding risk. Neither agent requires activation by P-gp, so the effect is increased edoxaban activity.
- Magnitude: Not studied with edoxaban. Capmatinib increased digoxin AUC by 47% and Cmax by 74%.
- Evidence: Theoretical (extrapolated). Onset unspecified. Severity on file: major.
- Management: Avoid if feasible. If unavoidable, reduce edoxaban dose per labeling recommendations for P-gp . Monitor for bleeding (clinical signs, hemoglobin) and function.
See the 2 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Edoxaban and Capmatinib Interact
The likely mechanism
of -mediated efflux transport by capmatinib
How to Manage the Edoxaban and Capmatinib Interaction
Your care team has good ways to handle this combination:
- They may consider whether both medicines are needed together, or whether another option fits better.
- If both are used, your edoxaban dose may need to be adjusted and individualized by your care team.
- Your team may monitor you more closely for bleeding.
What you can do: Keep taking both as prescribed. Tell your pharmacist or prescriber about all your medicines, and report unusual bruising, bleeding, blood in urine, or black stools right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Edoxaban or Capmatinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: TABRECTA oral tablets, capmatinib oral tablets
When capmatinib was given together with digoxin (a ), digoxin (0 to inf) rose by 47% and rose by 74%.1 In a small prospective single-sequence study of adult patients with MET-dysregulated advanced solid tumors refractory to currently available therapies (N=32), of capmatinib and digoxin, relative to digoxin alone, yielded digoxin geometric mean ratios of 1.47 (90% CI, 1.28 to 1.68) for AUC(infinity), 1.63 (90% CI, 1.42 to 1.89) for AUC(last), and 1.74 (90% CI, 1.43 to 2.13) for Cmax.
capmatinib also lengthened digoxin t(1/2) compared with digoxin alone (61.4 vs 47 hours), whereas Tmax was unchanged. Patients received capmatinib 400 mg twice daily for 12 days, with a single dose of digoxin 0.25 mg and rosuvastatin 10 mg administered on day 12.2
Edoxaban and Capmatinib: Common Questions
How serious is the Edoxaban and Capmatinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Edoxaban and Capmatinib interaction managed?
Your care team has good ways to handle this combination: They may consider whether both medicines are needed together, or whether another option fits better. If both are used, your edoxaban dose may need to be adjusted and individualized by your care team. Your team may monitor you more closely for bleeding. What you can do: Keep taking both as prescribed. Tell your pharmacist or prescriber about… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Edoxaban and Capmatinib Interaction
Ask in your own words about taking Edoxaban and Capmatinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (2)
- Product Information: TABRECTA(TM) oral tablets, capmatinib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2020. DailyMed
- Grande E, Giovannini M, Marriere E, et al: Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: a phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol 2021; 87(7):2867-2878.
Other Serious Interactions of Edoxaban and Capmatinib
Also serious with Edoxaban
Also serious with Capmatinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Edoxaban
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- CaffeineModerate
- Green TeaModerate
- + 215 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.